SA
VRCA icon

Sanctuary Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Sanctuary Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,000
Closed -$59.7K – 2509
2024
Q3 		$59.7K Buy
+6,000
New +$270K ﹤0.01% 2339

Other funds holding VRCA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanctuary Advisors's VRCA Position: Q4 2024 in Review

Sanctuary Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q4 2024, closing a stake of 6,000 shares — an estimated $59.7K sold.

Sanctuary Advisors first reported a position in VRCA in Q3 2024 and held it in 1 quarter. The position peaked at $59.7K in Q3 2024. 81 funds tracked by Wall St. Rank hold VRCA as of Q4 2024.

  • Sanctuary Advisors reported no remaining Verrica Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Sanctuary Advisors sold 6,000 Verrica Pharmaceuticals shares in Q4 2024, an estimated $59.7K.
  • Sanctuary Advisors first reported a position in Verrica Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Sanctuary Advisors's Verrica Pharmaceuticals position peaked at $59.7K in Q3 2024.
  • 81 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q4 2024.

Based on Sanctuary Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.